Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Shandong University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07647653CT.gov Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian Cancer | — | Not Yet Recruiting | — | — | — |
NCT07382713CT.gov Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer | — | Not Yet Recruiting | — | — | — |
NCT07321015CT.gov A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance | — | Not Yet Recruiting | — | — | — |
NCT07000344CT.gov A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor | — | Terminated | — | — | — |
NCT06954584CT.gov Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer | — | Recruiting | — | — | — |
NCT06188455CT.gov Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer | — | Not Yet Recruiting | — | — | — |
NCT06735326CT.gov Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer | — | Recruiting | — | — | — |
NCT06552858CT.gov Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer | — | Not Yet Recruiting | — | — | — |
NCT06541314CT.gov Fluzoparib Neoadjuvant Therapy for Ovarian Cancer | — | Unknown | — | — | — |
NCT06446206CT.gov Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer | — | Not Yet Recruiting | — | — | — |
Show 15 more trialsShow fewer
NCT06161272CT.gov Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi | — | Unknown | — | — | — |
NCT06081595CT.gov Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment | — | Not Yet Recruiting | — | — | — |
NCT06063070CT.gov First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer | — | Not Yet Recruiting | — | — | — |
NCT05585281CT.gov A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy | — | Unknown | — | — | — |
NCT05597527CT.gov Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer | — | Unknown | — | — | — |
NCT05551208CT.gov Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi | — | Recruiting | — | — | — |
NCT05479487CT.gov Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment | — | Not Yet Recruiting | — | — | — |
NCT05206890CT.gov A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer | — | Recruiting | — | — | — |
NCT05170594CT.gov A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer | — | Unknown | — | — | — |
NCT04718740CT.gov A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer | — | Completed | — | — | — |
NCT04517357CT.gov A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients | — | Completed | — | — | — |
NCT04229615CT.gov A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy | — | Unknown | — | — | — |
NCT03863860CT.gov A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients | — | Completed | — | — | — |
NCT03509636CT.gov A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer | — | Completed | — | — | — |
NCT03075462CT.gov A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fluzoparib (this asset) | Shandong University | P3 | B · 60 |
| Tisotumab Vedotin | Seagen Inc. | P2 | BB |
| TIL | Inge Marie Svane | P2 | BB |
| Olaparib | Shandong University | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | Kalinski, Pawel, MD, PhD | P3 | BB |
| Adriamycin | Genmab | P3 | BB |
| Carboplatin | Fudan University | P4 | BB |
| OTL-38 | On Target Laboratories, LLC | P4 | BB |
| Irinotecan | ARCAGY/ GINECO GROUP | P4 | BB |
+42 more in the Ovarian Cancer cohort
Other indications for Fluzoparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Peritoneal Carcinoma | — | P3 | B · 62 |
| Malignant Pancreatic Neoplasm | — | P3 | B · 62 |
| Breast Carcinoma | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fluzoparib in Ovarian Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fluzoparib-ovarian-cancer-33809
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →